Castle Biosciences Inc 2024年度报告

Dear Fellow Stockholders, 2024 was another year of strength for Castle. Fueled by our steadfast commitment to improving patient care, wenavigated a dynamic reimbursement and regulatory landscape while delivering exceptional performance resultsfor our stockholders. Our team's unwavering passion and collaborative spirit were instrumental in driving usforward, underscoring our strong, people-ƱŘŜťϙıĖIJîŜôťϙſēĖèēϙîôƱIJôŜϙĺŪŘϙculture and powers our organization. ĺIJťĖIJŪĖIJČϙĺŪŘϙťŘÍèħϙŘôèĺŘîϙĺċϙŜťŘĺIJČϙÍIJîϙèĺIJŜĖŜťôIJťϙƱIJÍIJèĖÍīϙŕôŘċĺŘıÍIJèôϠϙſôϙîôīĖŽôŘôîϙ͕͘Ϡ͏͖͐ϙťĺťÍīϙťôŜťϙŘôŕĺŘťŜϙĖIJϙ͑͏͓͑ϠϙÍIJϙĖIJèŘôÍŜôϙĺċϙ͕͒҇ϙèĺıŕÍŘôîϙťĺϙ͑͏͑͒ϠϙÍIJîϙċŪīī-ƅôÍŘϙŘôŽôIJŪôϙĺċϙщ͒͒͑ϙıĖīīĖĺIJϠϙŘôŕŘôŜôIJťĖIJČϙ͔͐҇ϙČŘĺſťēϙĺŽôŘϙ2023. Importantly, we believeťēôŜôϙôƄèôŕťĖĺIJÍīϙŘôŜŪīťŜϙŘôƲôèťϙťēôϙČŘĺſĖIJČϙÍîĺŕťĖĺIJϙĺċϙĺŪŘϙťôŜťŜϙÍıĺIJČϙēôÍīťēèÍŘôϙproviders due to the meaningful impact we are making in the lives of patients through our tests that can helpimprove treatment pathway decisions and, ultimately, outcomes. Empowering people, informing care decisions Ongoing evidence development is a key strategic priority at Castle and an important factor contributing to thecontinued adoption of our tests. In our dermatologic portfolio,ŜŕôèĖƱèÍīīƅϙĺŪŘϙ"ôèĖŜĖĺIJ"Ƅ®-Melanoma andDecisionDx®-SCC tests for patients with skin cancers, we delivered new data demonstrating theŜĖČIJĖƱèÍIJťϙclinicalvalue of our tests in guiding treatment pathway decisions. For DecisionDx-Melanoma, we shared impactful new data from our prospective, multi-center DECIDE studyèĺIJƱŘıĖIJČthe strength of the test to accurately identify patients with melanoma who have a low risk of metastasisand can thus safely forgo sentinel lymph node biopsy (SLNB) without experiencing a recurrence. As the onlymelanoma prognostic test shown to be associated with improved patient survival, this new data reinforces theŕĺſôŘϙĺċϙĺŪŘϙƲÍČŜēĖŕϙťôŜťϙťĺϙmeaningfully contribute to improved standards of care through more informed andpersonalized decision-making for patients with melanoma. Regarding DecisionDx-SCC, our test for patients with high-risk squamous cell carcinoma (SCC), numerouspublished studies in 2024ŽÍīĖîÍťôîϙÍIJîϙťēôIJϙèĺIJƱŘıôîϙťhe use of our test to predict which patients diagnosedſĖťēϙēĖČēϙŘĖŜħϙ‹ϙſĖīīϙīĖħôīƅϙIJĺťϙæôIJôƱťϙċŘĺıϙadjuvant radiation therapy (ART)ÍIJîϙſēĖèēϙŕÍťĖôIJťŜϙſĖīīϙīĖħôīƅϙæôIJôƱťϙfrom ART.iċϙŜĖČIJĖƱèÍIJèôϠϙťēôϙťſĺϙıŪīťĖ-center studies published in 2024 represent the largest and the secondīÍŘČôŜťϙŜťŪîĖôŜϙôŽôŘϙèĺıŕīôťôîϙťĺϙôŽÍīŪÍťôϙťēôϙôƯôèťĖŽôIJôŜŜϙĺċϙ
‡“. In our gastroenterology portfolio, we achieved yet anotherŜĖČIJĖƱèÍIJťϙıĖīôŜťĺIJô, surpassing 25,000 TissueCypher®test reports delivered since Castle acquired the testÍťϙťēôϙôIJîϙĺċϙ͑͏͑͐ϟϙWe have seen impressive growth andadoption of this test year after year, which we believe is driven by the tremendous value the test provides inpredicting a Barrett’s esophagus patient’s risk of developing esophageal cancer. This actionable information helpsclinicians make more informed decisions with their patients about appropriate surveillance and treatmentinterventions aligned to their personal estimated risk of disease progression. Looking Forward Throughout 2024, the unwavering commitment and passion of our exceptional Castle team helped us improve thecare of thousands of patients, propelling us toward our vision of transforming disease management by keepingŕôĺŕīôϙƱŘŜť.®ôϙīĺĺħϙèĺIJƱîôIJťīƅϙťĺϙťēôϙċŪťŪŘôϙċŘĺıϙwhat we believe isÍϙŕĺŜĖťĖĺIJϙĺċϙƱIJÍIJèĖÍīϙÍIJîϙĺŕôŘÍťĖĺIJÍīϙstrength and are energized by the numerous opportunities to further our impact and deliver long-term value for ourstockholders. On behalf of the entire Castle team, thank you for your continued trust in Castle. Sincerely, Derek Maetzold Founder, President & CEO UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 10-K (Mark One)ցANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934For the fiscal year ended December 31, 2024OR տTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934For the transition period from _________ to _________Commission File Number: 001-38984 CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) 77-0701774 (I.R.S. Employer Identification No.) (Zip Code) (Registrant’s telephone number, including area code) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YesտNoց Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YesտNoց Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file suchreports), and (2) has been subject to such filing requirements for the past 90 days. YesցNoտ Indicate by check mark whether the registrant has subm